Thalidomide for the treatment of myelodysplastic syndrome in Taiwan: Results of a phase II trial

Anticancer Research

Volumn 32, Issue 8, 2012, Pages 3415-3419

  Chung, Chih Yuan ^a   Lin, Sheng Fung ^b   Chen, Po Min ^c   Chang, Ming Chih ^d   Kao, Woei You ^e   Chao, Tsu Yi ^e   Hsiao, Liang Tsai ^c   Yen, Chuen Chuan ^c   Yang, Muh Hwa ^c   Hwang, Wei Shou ^f   Lin, Tung Liang ^g   Chiou, Tzeon Jye ^c   Chang, Cheng Shyong ^a  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d MACKAY MEMORIAL HOSPITAL   (Taiwan)

^e TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^f Chi Mei Foundation Hospital   (Taiwan)

^g CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Angiogenesis; Hematological improvement; Myelodysplastic syndromes; Thalidomide

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; HEMOGLOBIN; INTERLEUKIN 6; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; ARTICLE; ASTHENIA; BONE MARROW; CONSTIPATION; DISEASE DURATION; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DYSPNEA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOCALCEMIA; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REMISSION; SCORING SYSTEM; SOMNOLENCE; TAIWAN; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TAIWAN; THALIDOMIDE;

EID: 84865685836     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Tefferi A and Vardiman JW: Myelodysplastic syndromes. N Engl J Med 361: 1872-1885, 2009.
2. de Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C, Selleslag D, Ferrant A, Wijermans P, Mandelli F, Amadori S, Jehn U, Muus P, Boogaerts M, Zittoun R, Gratwohl A, Zwierzina H, Hagemeijer A and Willemze R: Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 98: 2326-2331, 2001.
3. Nakai K, Kanda Y, Fukuhara S, Sakamaki H, Okamoto S, Kodera Y, Tanosaki R, Takahashi S, Matsushima T, Atsuta Y, Hamajima N, Kasai M and Kato S: Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia 19: 396-401, 2005.
4. Shannon EJ, Morales MJ and Sandoval F: Immunomodulatory assays to study structure-activity relationships of thalidomide. Immunopharmacology 35: 203-212, 1997.
5. Haslett PA, Corral LG, Albert M and Kaplan G: Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187: 1885-1892, 1998.
6. Geitz H, Handt S and Zwingenberger K: Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31: 213-221, 1996.
7. Bauer KS, Dixon SC and Figg WD: Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 55: 1827-1834, 1998.
8. Candoni A, Raza A, Silvestri F, Lisak L, Galili N, Mumtaz M, Kikic F and Fanin R: Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes. Ann Hematol 84: 479-481, 2005.
9. Hayashi K, Hattori K and Toi F: Thalidomide is a highly effective treatment of MDS: a single-hospital experience in Japan. Int J Hematol 91: 725-727, 2010.
10. List AF: New approaches to the treatment of myelodysplasia. Oncologist 7(Suppl 1): 39-49, 2002.
11. Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F, du Randt M, Kaspar C, Goldberg C, Loew J, Dar S, Gezer S, Venugopal P and Zeldis J: Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98: 958-965, 2001.
12. Steensma DP and Bennett JM: The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 81: 104-130, 2006.
13. Strupp C, Germing U, Aivado M, Misgeld E, Haas R and Gattermann N: Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 16: 1-6, 2002.
14. Zorat F, Shetty V, Dutt D, Lisak L, Nascimben F, Allampallam K, Dar S, York A, Gezer S, Venugopal P and Raza A: The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol 115: 881-894, 2001.
15. COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms, (ed 5th). Rockville, MD, Food and Drug Administration, 1995.
16. Bodera P and Stankiewicz W: Immunomodulatory properties of thalidomide analogs: pomalidomide and lenalidomide, experimental and therapeutic applications. Recent Pat Endocr Metab Immune Drug Discov 5: 192-196, 2011.
17. De Sanctis JB, Mijares M, Suarez A, Compagnone R, Garmendia J, Moreno D and Salazar-Bookaman M: Pharmacological properties of thalidomide and its analogues. Recent Pat Inflamm Allergy Drug Discov 4: 144-148, 2010.
18. D'Amato RJ, Loughnan MS, Flynn E and Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085, 1994.
19. Kenyon BM, Browne F and D'Amato RJ: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 64: 971-978, 1997.
20. Turk BE, Jiang H and Liu JO: Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci USA 93: 7552-7556, 1996.
21. Sampaio EP, Sarno EN, Galilly R, Cohn ZA and Kaplan G: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173: 699-703, 1991.
22. Bouscary D, Legros L, Tulliez M, Dubois S, Mahe B, Beyne-Rauzy O, Quarre MC, Vassilief D, Varet B, Aouba A, Gardembas M, Giraudier S, Guerci A, Rousselot P, Gaillard F, Moreau A, Rousselet MC, Ifrah N, Fenaux P and Dreyfus F: A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies. Br J Haematol 131: 609-618, 2005.
23. Tamburini J, Elie C, Park S, Beyne-Rauzy O, Gardembas M, Berthou C, Mahe B, Sanhes L, Stamatoullas A, Vey N, Aouba A, Slama B, Quesnel B, Vekhoff A, Sotto JJ, Vassilief D, Al-Nawakil C, Fenaux P, Dreyfus F and Bouscary D: Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes. Leuk Res 33: 547-550, 2009.